Low-dose cyclophosphamide (CP) therapy induces immunogenic tumor cell death and decreases regulatory T cell (Treg) numbers in mice with transplantable tumors. Using the ret transgenic murine melanoma model that resembles human melanoma, we detected no beneficial antitumor effects with such treatment, despite a decrease in Tregs. On the contrary, low-dose CP enhanced the production of chronic inflammatory mediators in melanoma lesions associated with increased accumulation of Gr1 þ CD11b þ myeloid-derived suppressor cells (MDSCs), which exhibit elevated suppressive activity and nitric oxide (NO) production as well as inhibition of T-cell proliferation. Moreover, the frequencies of CD8 þ T cells in the tumors and their ability to produce perforin were decreased. To study whether the observed CP-induced MDSC expansion and activation also occurs under chronic inflammatory tumor-free conditions, mice exhibiting chronic inflammation were treated with CP. Similar to tumor-bearing mice, CP-treated inflamed mice displayed elevated levels of MDSCs with enhanced production of NO, reactive oxygen species, and a suppressed in vivo natural killer (NK) cell cytotoxic activity indicating CP effects on the host immune system independent of the tumor. We suggest that melanoma therapy with low-dose CP could be efficient only when combined with the neutralization of MDSC immunosuppressive function and chronic inflammatory microenvironment. support tumor development by stimulating pro-tumor mutations, resistance to apoptosis, and angiogenesis (Tan and Coussens, 2007; Mantovani et al., 2008) . Moreover, some of these factors induce the expansion and activation of immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) and M2 macrophages, in tumor lesions and in the periphery (
INTRODUCTION
Human malignant melanoma, known for its poor response to therapeutics, is one of the fastest growing cancers (MacKie et al., 2009) . Chemotherapy belongs to the standard melanoma treatment, although its efficacy is low. Moreover, chemotherapeutics in maximum tolerated doses can induce immunosuppression in tumor-bearing hosts (Gerber and Steinberg, 1976; Athanasiadou et al., 2002; Weiner and Cohen, 2002) . In contrast, low-dose chemotherapy stimulated antitumor immunity (Obeid et al., 2007; Zitvogel et al., 2008) . In particular, anthracyclins increased the tumor cell immunogenicity by inducing immunogenic cell death through efferocytosis (Obeid et al., 2007) . In contrast to classical apoptosis, which is considered as tolerogenic and anti-inflammatory (Zitvogel et al., 2008) , efferocytosis mediated by calreticulin (CRT) and LRP/91/Rac-1 pathway showed its immunostimulatory potential (Gardai et al., 2006) . Tumor progression is driven by chronic inflammation developed in the tumor microenvironment and represented by infiltrating leukocytes and soluble mediators (Baniyash, Cyclophosphamide (CP) at low doses has been recently applied in melanoma treatment combined with various immunotherapies (Koike et al., 2008; Quan et al., 2008) . In animal models, low-dose CP showed an antiangiogenic activity by killing circulating endothelial progenitors (Bertolini et al., 2003) and decreased nitric oxide (NO) concentrations in serum (Loeffler et al., 2005) . Moreover, CP reduced numbers and suppressed the function of regulatory T cells (Tregs) in tumor-bearing hosts (Lutsiak et al., 2005; Motoyoshi et al., 2006) . Furthermore, CP administration to tumor-bearing mice not only stimulated the mobilization of bone marrow (BM) dendritic cells (DCs) , but also activated their antigen-processing machinery by inducing pre-apoptotic surface translocation of CRT on tumor cells (Obeid et al., 2007; Sistigu et al., 2011) . However, the CP effects on chronic inflammatory environment that drives the tumor progression are poorly investigated.
In this study, we used the ret transgenic mouse model that, in contrast to transplantation models, shows similarity to human melanoma (Kato et al., 1998; Umansky et al., 2008) . Tumor-bearing mice developed metastases in lymph nodes (LNs), lungs, liver, brain, and BM (Umansky et al., 2008) . This metastatic profile resembles that of human melanoma (Houghton and Polsky, 2002; Patnana et al., 2011) . We found that although low-dose CP induced pre-apoptotic surface translocation of CRT on Ret melanoma cells in vitro and decreased Treg numbers in transgenic tumor-bearing mice in vivo, it could not delay the melanoma progression. CP stimulated the production of chronic inflammatory mediators associated with an elevation of MDSC frequencies and immunosuppressive activity in melanoma lesions. Mice with chronic inflammation induced by Bacillus Calmette-Guérin (BCG) (Vaknin et al., 2008) displayed a similar enhancement of MDSC frequencies and functions. Our data suggest that an enhancement of antitumor T-cell reactivity because of Treg depletion by low-dose CP can be efficiently blocked by activated MDSCs induced by chronic inflammation enhanced with CP treatment.
RESULTS

Low-dose CP induces immunogenic melanoma cell death leading to increased DC maturation in vitro
Ret melanoma cells established from skin melanomas of ret transgenic mice were treated in vitro with CP at low concentrations (5 or 10 mM). Cytotoxic effects were estimated by the staining with Annexin V and propidium iodide (PI) ( Figure 1 ). CP at both concentrations induced a significant increase in the numbers of dead melanoma cells at day 2 after treatment ( Figure 1b ). Analysis of immunogenic cell death marker, CRT, revealed its appearance on some nonapoptotic AnnexinV -PI -Ret cells (i.e., before phosphatidylserine translocation) at day 2 of coincubation with 5 mM but not 10 mM CP (Figure 1c ). Moreover, these cells displayed a significantly higher level of CRT expression ( Figure 1d ). Therefore, an increase in CRT expression on melanoma cells upon coculture with CP was detected before the beginning of apoptosis, suggesting an induction of immunogenic cell death. To test directly the increased immunogenicity of Ret cells upon treatment with 5 mM CP, we cocultured these pretreated cells with DCs generated from normal BM precursors. The frequency of CD11c þ MHC class II þ DCs was elevated upon coculture with pretreated melanoma cells, as compared with DCs coincubated with untreated Ret cells (Supplementary Figure S1a online). Interestingly, pretreatment of melanoma cells with 10 mM CP failed to upregulate the major histocompatibility complex class II expression on DCs (Supplementary Figure S1b online) that correlated with the failure of CP at this concentration to induce CRT on melanoma cells (Figure 1c and d). Furthermore, DCs cocultured with tumor cells pretreated with 5 mM CP displayed an increased expression of costimulatory molecules, CD80 and CD40 (Supplementary Figure S1b and c online). Another costimulatory molecule, CD86, was also upregulated under similar coculture conditions (data not shown).
Low-dose CP downregulates Tregs in vivo
As low doses of CP (1-2.5 mg per mouse) can decrease Treg numbers and suppressive activity in tumor-bearing mice (Lutsiak et al., 2005; Motoyoshi et al., 2006) , we tested such CP effect on ret transgenic mice with skin melanoma. At day 7 after the therapy onset, Treg frequencies in skin tumors were decreased in a dose-dependent manner, as compared with those in untreated animals (Figure 2a ). A significant reduction of Treg frequencies was also detected in the spleen of these mice ( Figure 2b ). As melanoma microenvironment is characterized by chronic inflammation, we applied a murine model of BCG-induced chronic inflammation (Vaknin et al., 2008) to investigate CP-mediated Treg alterations in the absence of tumors. Similar to tumor-bearing animals, CP injection at both the low doses significantly reduced Treg frequencies in the peripheral blood ( Figure 2c ) and spleen ( Figure 2d ) of inflamed mice, as compared with CP-untreated animals.
CP therapy provides no antitumor effects and enhances chronic inflammatory mediators Next, we studied the effects of low-dose CP (1 or 2.5 mg per mouse) on melanoma progression in transgenic mice. Despite the potential induction of tumor cell immunogenicity and the decrease in Treg frequencies, the survival of CP-treated tumorbearing mice was not significantly longer than that of untreated mice (Figure 3a ). Furthermore, we found no delay in melanoma progression if low-dose CP therapy was combined with the vaccination by a peptide derived from the melanoma-associated antigen tyrosinase-related protein-2 ( Figure 3a ).
Next, we assessed the pattern of different chronic inflammatory mediators in tumor lesions. A significant increase in concentrations of GM-CSF, IL-1b, IL-5, IL-10, IFN-g, and tumor necrosis factor-a was found in lysates from skin tumors and metastatic LNs of mice treated with a single CP injection (2.5 mg per mouse), as compared with untreated tumorbearing animals (Figure 3b and c). Such accumulation of inflammatory factors could support the MDSC recruitment and activation in tumor lesions (Baniyash, 2006; Gallina et al., 2006; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009; Meyer et al., 2011) . 
CP-induced inflammation mediates an elevation of MDSC frequencies
Gr1 þ CD11b þ MDSCs were quantified in skin tumors and spleens of transgenic mice treated with low-dose CP (Figure 4a -c). We demonstrated a substantial accumulation of MDSCs among leukocytes infiltrating melanomas at day 21 after the therapy with 2.5 mg CP, as compared with untreated mice (Figure 4b ). Moreover, both 1 and 2.5 mg of CP upregulated MDSC frequencies in the spleen of tumor-bearing mice (Figure 4c ). To investigate whether the CP-induced MDSC accumulation also occurs under tumor-independent chronic inflammatory conditions, we treated mice exhibiting BCG-induced chronic inflammation with a single injection of low-dose CP (1 or 2.5 mg per mouse). Mice challenged with BCG alone displayed an MDSC accumulation in both the peripheral blood ( Figure 4d ) and spleen ( Figure 4e ). CP treatment resulted in a further MDSC elevation in the peripheral blood and in a tendency of increase in the spleen as compared with animals injected with BCG alone (Figure 4d and e).
Next, we tested whether CP could modulate in healthy mice (in the absence of chronic inflammation) the frequency of immature Gr1 þ CD11b þ cells, which are considered as MDSCs in tumor-bearing animals (Gabrilovich and Nagaraj, 2009) . Upon an injection of 2.5 mg CP, these cells were expanded in the spleen, peripheral blood, and LN, but not in BM, as compared with untreated mice (Figure 4f ). No alterations of cytokine or growth factor levels were detected in the lymphoid organs of CP-treated healthy mice (data not shown).
MDSCs from CP-treated mice display an enhanced suppressive activity
As NO and reactive oxygen species (ROS) are considered to be among the key factors of the MDSC-induced immunosuppression Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg, 2010) , their production was assessed with low-dose CP therapy in both mouse models ( Figure 5 ). A significant increase of NO production in tumor-infiltrating MDSCs from mice treated with 2.5 mg per mouse was observed as compared with untreated animals (Figure 5b ). Similar findings were obtained in mice with BCG-induced chronic inflammation upon an injection of low-dose CP. Levels of NO and ROS production in MDSCs from the peripheral blood of CP-treated mice were substantially higher than in chronically inflamed CP-untreated animals (Figure 5c and d). However, in spleen MDSCs, although the NO and ROS production was already significantly enhanced by the chronic inflammation, no further elevation of both factors was detected after the CP therapy (Figure 5e and f). In healthy mice, immature CD11b þ Gr1 þ cells showed no enhanced ROS production with CP treatment (data not shown).
CP treatment aggravates chronic inflammation-induced alterations in immune effector cells
Next, we studied whether the CP-mediated stimulation of MDSCs could enhance their ability to suppress T-cell and natural killer (NK) cell functions. MDSCs from tumors of animals treated with 2.5 mg CP were cocultured with stimulated syngeneic normal splenocytes. Such MDSCs suppressed T-cell proliferation stronger than those isolated from CPuntreated tumor-bearing mice (Figure 6a and b) . Analyzing tumor-infiltrating CD8 þ T lymphocytes in CP-treated mice (1 mg per mouse), we found a significant reduction in the frequency of these cells as compared with untreated mice (Supplementary Figure S2a online) . Moreover, we observed a significant downregulation of intracellular perforin concentrations in CD8 þ tumor-infiltrating T lymphocytes isolated from CP-treated mice (2.5 mg per mouse), suggesting their diminished cytotoxic function (Po0.05; Supplementary Figure S2b online). A strong tendency for a decrease in perforin levels was also detected in CD8 þ T cells from metastatic LNs of these mice ( Supplementary Figure S2b online) .
In the BCG-induced chronic inflammatory model, we focused on the modulation of NK cell functions. Splenocytes from syngeneic (C57BL/6) and allogeneic (BALB/c) mice were labeled with low and high carboxyfluorescein succinimidyl ester concentrations, respectively, and administered into C57BL/6 mice. The immunosuppression was verified by the impaired ability of recipients to clear allogeneic cells by cytotoxic NK cells. To test the contribution of other cells in this effect, we depleted NK cells that resulted in almost complete retention of allogeneic cells (data not shown). A substantial decline of allogeneic cell clearance was detected in the peripheral blood of chronically inflamed mice upon treatment with low-dose CP as compared with chronically inflamed CP-untreated mice (Figure 6c) . A similar tendency of reduced clearance was also observed in the spleen of CPtreated mice ( Supplementary Figure S3 online) . Moreover, MDSCs isolated from chronically inflamed animals treated with 2.5 mg CP blocked proliferation of cocultured stimulated syngeneic normal T cells (data not shown).
DISCUSSION
In this study, we highlight the complex effects of CP treatment on the tumor and host's immune system showing that it affects not only tumor cells but displays diverse effects on immune cells. Treatment of Ret melanoma cells in vitro with CP at 5 and 10 mM, which were reported to be low , induced an enhanced CRT expression on AnnexinV -PIlive cells. CRT is involved in cell adhesion, folding of new synthesized glycoproteins, and lectin-like chaperone activity (Obeid et al., 2007) . However, in cancer cells, rapid CRT mobilization to the cell surface at the beginning of apoptosis (before the phosphatidylserine translocation) led to its fast recognition by DCs through CD36-a v b 3 ,C1qR receptor (Storkus and Falo, 2007) . This phenomenon was described as an immunogenic cell death because the phagocytosis of such apoptotic tumor cells stimulated DCs, promoting antitumor T-cell responses (Obeid et al., 2007) . Our data on the partial restoration of DC maturation upon their coculture with pretreated Ret cells suggested a CP-mediated development of immunogenic death in these tumor cells. The administration of CP at low doses (1-2.5 mg per mouse) (Motoyoshi et al., 2006; Sistigu et al., 2011) in vivo was found to reduce frequencies and suppress the function of Tregs in tumor-bearing hosts (Lutsiak et al., 2005; Motoyoshi et al., 2006; Liu et al., 2010; Sistigu et al., 2011) . The results presented herein confirm these observations for melanomabearing transgenic mice. We also demonstrated a CP-mediated Treg downregulation in mice with chronic inflammation induced by BCG administration, indicating that CP-mediated reduction in Treg frequencies is tumor independent.
However, investigating the effects of low-dose CP on melanoma progression revealed no increase of mouse survival, even though immunogenic tumor cell death was induced and Treg levels were reduced. This lack of antitumor effects led us to suggest that CP modulated immunosuppressive mechanisms in tumor-bearing mice responsible for ineffective antitumor reactivity. One of the critical factors inducing immune suppression and supporting tumor progression is chronic inflammation that develops in the tumor microenvironment (Baniyash, 2006 Ostrand-Rosenberg and Sinha, 2009; Ostrand-Rosenberg, 2010; Rook and Dalgleish, 2011) . Using the ret transgenic mouse model, we have recently demonstrated an accumulation of various chronic inflammatory factors and MDSCs in melanoma lesions (Zhao et al., 2009; Meyer et al., 2011) . In this study, we found that low-dose CP therapy induced a significantly higher production of several key inflammatory mediators, such as GM-CSF, IL-1b, IL-5, IL-10, IFN-g, and tumor necrosis factora, in skin tumors and metastatic LNs than in untreated tumorbearing animals. As all these factors are important for MDSC expansion and activation (Baniyash, 2006; Gallina et al., 2006; Tu et al., 2008; Gabrilovich and Nagaraj, 2009; Greifenberg et al., 2009; Ostrand-Rosenberg and Sinha, 2009; Ostrand-Rosenberg, 2010; Stathopoulos et al., 2010; Meyer et al., 2011) and as under CP treatment, antitumor responses were not evident, we analyzed MDSCs as being potential targets for the observed immunomodulation. In CP-treated mice, a significant increase in MDSC frequencies was observed in primary tumors, BM, and spleen, as compared with already elevated MDSC numbers in CPuntreated tumor-bearing mice. Increased circulating MDSC frequencies were previously reported in breast cancer patients and mice, with B16 melanoma injected with CP along with doxorubicin (Diaz-Montero et al., 2009; Salem et al., 2010) . However, in contrast to our investigation, CP was used in both studies at standard high doses. Although Liu et al. (2010) demonstrated an expansion of tumor-infiltrating MDSCs after a single low-dose CP injection, the modulation of MDSC functions and chronic inflammatory microenvironment was not addressed. We found that the MDSC enrichment in tumorbearing mice with low-dose CP therapy was associated with an increased immunosuppressive activity. Moreover, such treatment stimulated NO production that was detected directly in these cells, which is in contrast to findings by Loeffler et al. (2005) , who measured reduced NO levels in the serum of tumor-bearing mice after CP treatment. These discrepancies might be because of the differences between transplantation models and the autochthonous model used in our study.
To characterize the role of chronic inflammation in CPmediated effects on MDSCs, we applied a mouse model of BCG-induced chronic inflammation without the tumor impact (Vaknin et al., 2008) . Similar to tumor-generated conditions, a significant increase in MDSC frequencies and enhanced ability to produce immunosuppressive mediators (NO and ROS) with CP administration was demonstrated. Interestingly, although a CP-induced increase in the MDSC population was detected in normal mice, they failed to display an enhanced NO and ROS production. These findings suggest that chronic inflammatory conditions developing in different pathologies could be responsible for the enrichment and activation of MDSCs with low-dose CP therapy. The signaling mechanisms responsible for such CP effects are currently under investigation.
A remarkable MDSC stimulation in both mouse models after low-dose CP treatment was found to be associated with a marked downregulation of CD8 þ T-cell and NK cell functions. This could be explained by the increased MDSC capacity to produce NO and ROS, known to induce anergy of reactive T cells (Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009) . Therefore, the immunostimulatory effects of low-dose CP (e.g., a Treg depletion and induction of immunogenic tumor cell death) could be abrogated because of MDSC expansion and activation in developing melanoma. This is in agreement with a recently published report on the inability of low-dose CP to improve immunological and clinical effects of the multipeptide vaccination of melanoma patients (Slingluff et al., 2011) , suggesting a possible MDSC activation. Interestingly, another study demonstrated that low-dose CPinduced tumor-specific T-cell responses correlated with improved clinical outcome in breast cancer patients (Ge et al., 2011) . These observations raise the question of the predominant involvement of different immunoregulatory cells (MDSCs or Tregs) in the progression of various tumor types that needs further investigation.
Taken together, we found that a single injection of low-dose CP induced an immunogenic melanoma cell death and downregulated Treg frequencies in transgenic melanoma mouse model. Such therapy led to a further accumulation of chronic inflammatory mediators, inducing an enrichment and activation of MDSCs in melanoma lesions that abrogate potential CP antitumor effects. Similar changes were also induced by CP in chronic inflammatory mouse model without any tumor impact. CP-induced enhancement of immunosuppression resulted in the impairment of innate and adaptive immunity as reflected by the downregulation of CD8 þ T-cell and NK cell functions. We suggest that tumor immunotherapy with low-dose CP should include neutralization of chronic inflammatory factors and block MDSC immunosuppressive functions, which are enhanced with CP treatment.
MATERIALS AND METHODS
Mice
Ret transgenic mice provided by Dr I Nakashima (Chubu University, Aichi, Japan) were kept in the specific pathogen-free facility of German Cancer Research Center (Heidelberg, Germany) Experiments were conducted on female and male tumor-bearing mice that were 6-7 weeks of age. Female C57BL/6 mice, 7-8 weeks of age, were purchased from Harlan (Jerusalem, Israel) and kept at the Hebrew University specific pathogen-free facility (Jerusalem, Israel). Animal experiments were conducted in accordance to the government and institutional guidelines and regulations.
Reagents and antibodies
Medium RPMI-1-640 was purchased from PAA (Coelbe, Germany). CP was from Sigma (Munich, Germany). Diaminofluoresciein-2 diacetate and aminophenyl fluorescein were from Cell Technology (Mountain View, CA). Rat anti-mouse directly conjugated mAbs (CD3-PerCP-Cy5.5, CD4-FITC, CD8-APC-Cy7, CD25-APC, CD45.2-PerCP-Cy5.5, CD11b-PE, Gr1-PE-Cy7, I-A b -FITC, CD40-PE, CD80-PE, CD86-PE, and CD11c-APC) were from BD Biosciences (Heidelberg, Germany). FoxP3 fixation/permeabilization kit, rat anti-mouse Foxp3-PE mAbs, and AnnexinV/PI apoptosis staining kit were from eBioscience (San Diego, CA). Purified rabbit anti-mouse CRT (Santa Cruz, Heidelberg, Germany) and goat anti-rabbit IgG-AlexaFluor 488 (Invitrogen, Karlsruhe, Germany) were also used.
Mouse model of chronic inflammation
BCG (Difco Laboratories, Detroit, MI) was administrated into C57BL/ 6 mice, as previously described (Vaknin et al., 2008) .
CP treatment in vitro and in vivo
Ret cells established from skin melanoma of transgenic mice were incubated with 5 or 10 mM of CP for 24 hours. DCs were generated from the BM of normal mice as described (Shurin et al, 2009 ). Before co-incubation with DCs, CP-treated Ret cells were washed twice. Transgenic tumor-bearing mice received a single intraperitoneal injection of CP (1 or 2.5 mg per mouse). Mice with BCG-induced chronic inflammation were injected intraperitoneally with 1 or 2.5 mg CP 2 days after the second BCG injection. Control groups consisting of tumor-bearing transgenic mice or BCG-treated animals received phosphate-buffered saline.
Immunization
Tumor-bearing transgenic mice were immunized with the tyrosinaserelated protein-2-derived peptide (SVYDFFVWL), as described (Firat et al, 1999) , simultaneously with the CP administration.
Flow cytometry
Single-cell suspensions prepared from the tumor, spleen, LN, and BM were treated with Fc-block and mAbs for 30 minutes at 4 1C. Acquisition was performed by multicolor flow cytometry using FACSCanto II with FACSDiva software (both from BD Biosciences) with dead cell exclusion. FlowJo software (Tree Star, Ashland, OR) was used to analyze at least 100,000 events.
Bio-Plex assay
Snap-frozen tumor and LN samples were disrupted and treated with lysis solution (Bio-Rad, Munich, Germany). Concentrations of inflammatory factors were measured by multiplex technology (Bio-Rad) according to the manufacturer's protocol.
In vitro proliferation assay
CD11b þ cells were isolated from tumors of transgenic mice using CD11b þ MicroBeads isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol. The proportion of Gr1 þ CD11b þ MDSCs in selected population was B80%. C57BL/6 splenocytes were labeled with carboxyfluorescein succinimidyl ester (Invitrogen; final concentration of 2.5 mM), stimulated with anti-CD3 and anti-CD28 mAbs (0.5 mg ml À 1 each), and cocultured with MDSCs in a ratio of 1:1 for 96 hours. T-cell proliferation was evaluated using flow cytometry.
In vivo cytotoxicity assay
Specific clearance of carboxyfluorescein succinimidyl ester-labeled allogeneic splenocytes in C57BL/6 mice was performed and evaluated as described before (Vaknin et al., 2008) .
Statistical analysis
Results were assessed with Student's t-test and Mann-Whitney U-test using GraphPad Prism software (San Diego, CA). Differences in values at Po0.05 were considered significant.
